Seattle, WA – March 26, 2019
NanoSurface Biomedical, a leading provider of biomimetic cell-based assay products and services, announced today the launch of the NanoSurface Car(ina)™ platform for highly predictive pre-clinical drug screening, using structurally matured human induced pluripotent stem cell (iPSC) derived heart tissues. This innovative human stem cell-based technology enables drug developers to accurately test the safety and efficacy of new drugs earlier in the drug development process and promises to help get safer medicines to market in less time and at lower cost.
Read the full press release here.
About NanoSurface Biomedical
NanoSurface Biomedical is a biotechnology company based in Seattle, WA that develops biomimetic technologies to enhance cell-based assays and accelerate drug development. NanoSurface was founded in 2015.